Overview

Phase I/Ib Multiple Ascending Dose Study in China

Status:
Completed
Trial end date:
2021-02-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the maximum tolerated dose (MTD) and pharmacokinetics (PK) of Avelumab monotherapy in Chinese subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Antibodies, Monoclonal
Avelumab